1125 Trenton-Harbourton Road
P.O. Box 200
Titusville , NJ 08560
Related Content
May 31, 2022 — Findings from the XARELTO (rivaroxaban) Phase 3 COMPASS Long-Term Open Label Extension (LTOLE) study and ...
May 31, 2022
Feature | Coronavirus (COVID-19)| By Dave Fornell, Editor
(This story was updated May 7, 2021 in the last subheaded section) April 13, 2021 — The U.S. Food and Drug ...
April 13, 2021
March 1, 2021 — The U.S. Food and Drug Administration (FDA) issued an emergency use authorization (EUA) for the third ...
March 01, 2021
October 17, 2018 — The U.S. Food and Drug Administration (FDA) has cleared an additional indication for rivaroxaban ...
October 17, 2018
June 29, 2018 — Results from the MERCURY PE study showed that low-risk pulmonary embolism (PE) patients treated with ...
June 29, 2018
March 14, 2018 — A late-breaking analysis of the landmark COMPASS study presented at the American College of Cardiology ...
March 14, 2018
February 19, 2018 — A late-breaking analysis of the landmark COMPASS study was presented at the 2018 International ...
February 19, 2018
October 18, 2017 — Results from the pivotal Phase 3 COMPASS study found that the Xarelto vascular dose plus aspirin 100 ...
October 18, 2017
June 29, 2017 — Janssen Research & Development LLC announced the U.S. Food and Drug Administration (FDA) accepted for ...
June 29, 2017
February 9, 2017 — Janssen Research & Development LLC (Janssen) announced that the Phase 3 COMPASS trial is stopping ...
February 09, 2017